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The porphyrias are a group of inherited metabolic 
disorders that are associated with a specific 
enzymatic abnormality in the haem biosynthesis 
pathway. Porphyrias are traditionally classified as 
hepatic or erythropoietic according to the site of 
accumulation of haem precursors, but classifications reflecting the 
clinical presentation, such as acute and cutaneous, may be more 
practical.[1] The acute porphyrias that are inherited in an autosomal 
dominant pattern include acute intermittent porphyria (AIP), 
variegate porphyria (VP) and hereditary coproporphyria, while 
acute porphyria due to d-aminolaevulinic acid (ALA) dehydratase 
deficiency is an autosomal recessively inherited condition.
AIP is estimated to occur in one in 75  000 people in Europe, 
except in Sweden, where the condition is seen in one in 1 000 
owing to a founder effect.[1,2] Similarly, VP is estimated to occur in 
one of 150 000 people in Europe, but the prevalence in SA is much 
higher, estimated at 3/1 000 in the white population as a result 
of a founder mutation that was introduced from the Netherlands 
in 1688.[3] An acute porphyric attack may be precipitated by several 
factors, including starvation, certain medications and hormonal 
fluctuations. The typical attack begins with severe abdominal pain 
and autonomic hyperactivity, followed by psychiatric disturbances 
and possibly neuropathy. Whereas most patients recover well from 
acute porphyric attacks, neurological complications may develop; 
these include electrolyte disturbances and seizures, confusional 
states, autonomic dysfunction and severe quadriparesis.[1]
We describe the clinical presentation and outcome of four patients 
with acute porphyria who presented to a neurology unit in Pretoria, 
South Africa (SA), during one year, emphasising that the presentation 
of acute porphyric neuropathy may be similar to that of Guillain-
Barré syndrome and occur in the absence of acute abdominal pain. 
The occurrence of AIP in the black population is highlighted and 
some clinically relevant points regarding treatment are detailed.
Three patients presented to Steve Biko Academic Hospital with 
progressive quadriparesis, and one to a private hospital with acute 
abdominal pain followed by rapidly progressive quadriparesis. Two 
patients had started antiretroviral therapy before the development 
of symptoms, and one had started antituberculosis therapy. All 
had marked weakness with depressed reflexes, and showed varying 
degrees of confusion in the ward.
An initial diagnosis of Guillain-Barré syndrome led to the 
administration of intravenous immunoglobulins in two patients.
On testing for porphyria, it was found that two patients had AIP 
and two VP. Electrophysiological investigations revealed features of a 
severe mainly motor axonal neuropathy in all (Table 1). Two patients 
deteriorated to the point of requiring mechanical ventilation, and 
one of them died due to complications of critical illness. Haemin 
was administered to three patients, but the process of obtaining this 
medication was slow, proving a challenge in the state hospital setting, 
so the recommended early administration was delayed. As a result, the 
surviving patients showed minimal recovery and remained severely 
disabled.
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The hepatic porphyrias are a group of rare metabolic disorders, each of which is associated with a specific enzymatic alteration in the haem 
biosynthesis pathway. In South Africa (SA), a high incidence of variegate porphyria (VP) is seen as a result of a founder effect, but acute 
intermittent porphyria (AIP) is also encountered. The development of acute neurovisceral attacks is related to environmental factors, including 
medications, hormones and diet. A possible manifestation of a severe attack is rapidly progressing quadriparesis, which may mimic Guillain-
Barré syndrome. We present four such cases, highlighting that acute porphyria should be considered in the differential diagnosis of Guillain-
Barré syndrome. Three patients presented to Steve Biko Academic Hospital, Pretoria, SA, with progressive quadriparesis, and one to a private 
hospital with acute abdominal pain followed by rapidly progressive quadriparesis. Two patients had started antiretroviral therapy before the 
development of symptoms, and one had started antituberculosis therapy. All patients had marked weakness with depressed reflexes, and 
showed varying degrees of confusion. An initial diagnosis of Guillain-Barré syndrome led to administration of intravenous immunoglobulins 
in two patients. On testing for porphyria, it was found that two patients had AIP and two VP. Electrophysiological investigations revealed 
severe mainly motor axonal neuropathy in all. Two patients deteriorated to the point of requiring mechanical ventilation, and one of them 
died due to complications of critical illness. Haemin was administered to three patients, but the process of obtaining this medication was slow, 
which delayed the recommended early administration. The surviving patients showed minimal recovery and remained severely disabled. 
Porphyric neuropathy should always be considered as a differential diagnosis in a patient with an acute neuropathy, especially in SA. Absence of 
abdominal pain does not exclude the possibility of porphyria, and attacks may be precipitated by antiretroviral and antituberculosis medication. 
The outcome of our patients was not favourable; specifically, obtaining haemin was a challenge in the state hospital setting.
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Case reports
Case 1
A 42-year-old black woman presented with an acute onset of pro-
gressive quadriparesis that had developed over 4 days. She was 
HIV-positive and antiretroviral therapy had been initiated 4 weeks 
previously; at around that time, she had also had a flu-like illness. In 
addition to the weakness, she experienced paraesthesiae and numbness 
over the extremities. In the ward, she was intermittently confused. On 
examination, she showed facial weakness and a global power of grade 
2/5 with areflexia and loss of sensation of the ‘bathing suit’ type. A 
diagnosis of possible Guillain-Barré syndrome was made and she was 
treated with intravenous immunoglobulins (IVIG). It was also noted 
that her urine was a dark brown colour, and porphyria screening was 
requested. Her condition deteriorated in the ward and she required 
intubation and ventilation in the intensive care unit. The urinary 
porphobilinogen (PBG) level was 378 µmol/L (reference value <9), the 
faecal porphyrins were marginally elevated at 374 nmol/g dry weight 
(reference value <200) and the plasma emission spectrum was maximal 
at 619 nm. A final diagnosis of AIP was made. Lumbar puncture 
showed high cerebrospinal fluid (CSF) protein levels and serum 
biochemical investigations revealed hyponatraemia (126 mmol/L, 
reference range 136 - 145). Electromyography (EMG) demonstrated 
low compound muscle action potential (CMAP) amplitudes in all four 
limbs, as well as reduced sensory nerve action potentials. Unfortunately 
it was impossible to obtain haemin for this patient. She developed 
a pulmonary embolism, received intensive physiotherapy and was 
eventually extubated. The weakness improved marginally, but she 
remained severely weak and was still bedridden after 2 months.
Case 2
A 34-year-old black man was admitted with progressive quadri-
paresis that had developed over 3 - 4 weeks. He had had a respiratory 
tract infection before the onset of symptoms and had possibly 
received antibiotics. He also complained about a cold sensation in 
his limbs, as well as hoarseness and a soft voice. On examination, 
he appeared confused and had a bovine cough (later confirmed to 
be due to left-sided vocal cord paralysis), power of grade 0/5 in the 
arms proximally and 3/5 distally, and weakness in the legs of 4/5 
proximally and 5/5 distally. The deep tendon reflexes were absent 
and glove-and-stocking-type sensory loss was evident. The patient 
was initially treated with IVIG for possible Guillain-Barré syndrome. 
However, investigations for porphyria revealed a urinary PBG level 
of >100 µmol/L, total urinary porphyrins of 2 236 nmol/L (reference 
value <300 nmol/L), faecal porphyrins of 333 nmol/g dry weight, and 
a plasma peak at 619 nm on emission spectrofluorimetry. A diagnosis 
of AIP was made, and it was discovered that the patient’s sister had 
Table 1. Motor nerve conduction studies of patients
Patient
Median nerve Ulnar nerve Peroneal nerve Tibial nerve
DL
(ms)
Amp
(mV)
NCV
(m/s)
DL
(ms)
Amp
(mV)
NCV
(m/s)
DL
(ms)
Amp
(mV)
NCV
(m/s)
DL
(ms)
Amp
(mV)
NCV
(m/s)
Patient 1
Right distal 4.1 1.08 51.2 3.0 2.21 64.7 4.6 1.46 41.5 4.3 4.57 47
Right proximal 8.2 0.860 7.65 1.89 12.85 1.3 12.5 3.63
Left distal 3.55 2.12 50 2.75 2.25 72.3 8.85 0.072 64.6 4.3 4.17 48.1
Left proximal 7.75 1.36 6.0 1.48 14.5 0.06 12.2 5.47
Patient 2
Right distal 3.5 3.6 46.8 2.8 3.2 40.9 4.3 3.2 38.6 7.8 11.2 35.6
Right proximal 8.2 3.6 9.5 2.7 13.5 2.9 19.2 10.6
Left distal 3.2 3.0 54.2 2.5 5.8 48.2 4.4 2.3 37.2 3.7 9.7 40
Left proximal 8.0 2.9 9.4 4.5 13.8 1.6 14.2 8.0
Patient 3 (baseline)
Right distal 5.1 3.3 3.3 3.7 43.1 5.8 1.5 38.1 4.7 7.5 31.4
Right proximal 10.4 0.470 10.3 2.4 16 1.2 16.8 4.6
Left distal
Left proximal
Patient 3 (after 2 mo)
Right distal Absent
Right proximal Absent
Left distal 4.9 0.101 42.2 Absent Absent
Left proximal 10.35 0.079 6.2 0.021
Patient 4
Right distal 3.1 0.100 33.8 2.5 3.3 47.9 4.1 6.5 41.8
Right proximal 11.2 2.3 13.2 5.8
Left distal
Left proximal
DL = distal latency; Amp = amplitude; NCV = nerve conduction velocity; ms = milliseconds; mV = millivolts; m/s = metres per second.
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also previously been diagnosed with this condition. The CSF protein 
level was within normal limits and hyponatraemia (128 mmol/L) 
was present. On EMG, the patient had low CMAP amplitudes and 
slowing of conduction velocity in motor and sensory nerves, while 
an electroencephalogram showed generalised slowing at 6 - 7 Hz. 
The patient received a course of haemin, which was only available 6 
weeks after admission. He improved somewhat, but remained weak 
and quadriparetic with persistent hoarseness.
Case 3
A 69-year-old white woman presented with weakness, which had 
developed over a 10 - 14-day period, and complaints of numbness 
and paraesthesiae in the hands and feet. She was known to have 
VP and reported that her last acute porphyric attack some 30 
years previously had been characterised by abdominal pain and an 
impaired level of consciousness. The current attack was probably 
precipitated by antituberculosis treatment that had been started for 
pulmonary tuberculosis. The patient’s weakness quickly progressed 
to respiratory failure, necessitating intubation and ventilation. On 
examination, she showed facial weakness and a global power of only 
grade 2/5 with 1+ reflexes in the upper limbs and absent reflexes in 
the lower limbs. The urinary PBG level was elevated at 201 µmol/L, 
total urinary porphyrins were 1 516 nmol/L and faecal porphyrins 
were markedly elevated at 5 736 nmol/g dry weight. The plasma 
emission spectrum revealed a peak at 625 nm, consistent with a 
diagnosis of VP. Molecular genetic analysis confirmed the presence 
of the R59W mutation. Severe hyponatraemia developed with the 
administration of glucose solutions, and although haemin was 
finally administered after 3 weeks, the patient’s clinical condition 
continued to deteriorate. She developed multiple complications 
related to critical care and ultimately died due to sepsis after 4 
months in the intensive care unit.
Case 4
A 32-year-old white man presented with acute abdominal pain, con-
fusion and hallucinations, followed by rapidly progressive weakness 
of the arms more than the legs and generalised seizures. He had 
taken antiretroviral therapy for post-exposure prophylaxis before 
this admission. On examination, he was acutely delirious, with facial 
weakness, proximal weakness of grade 0/5 and distal weakness of 
1/5 in the arms, and proximal weakness of 2/5 and distal weakness 
of 4/5 in the legs. The ankle reflexes were the only reflexes that 
were retained. The urine was a dark brown colour and porphyria 
investigations revealed a positive urinary PBG screening test, total 
urinary porphyrins of 1 429 nmol/L and markedly elevated faecal 
porphyrins. The plasma emission spectrum was maximal at 625 nm, 
in keeping with VP. The R59W mutation was also positive. Haemin 
was administered after 5 days, leading to amelioration of the delirium 
and seizures. Although the weakness in the legs improved somewhat, 
the arms remained severely weak even at follow-up 4 months later.
Discussion
AIP and VP form part of the acute hepatic porphyrias, which 
are associated with a range of extrahepatic, gastrointestinal and 
neurological and psychiatric manifestations.[4] During an acute attack, 
haem precursors accumulate in front of the deficient enzyme, which 
in AIP is porphobilinogen deaminase and in VP protoporphyrinogen 
oxidase. The excess porphyrin metabolites are then excreted in the 
urine and faeces according to a characteristic pattern. In AIP urinary 
ALA and PBG are markedly elevated, and in VP urinary ALA, PBG 
and coproporphyrinogen levels are high. Protoporphyrinogen is 
usually markedly elevated in the faeces in VP.[4] These patterns were 
also observed in our patients, and genetic confirmation was available 
in both of our patients with VP.
Typical acute porphyria attacks begin with severe abdominal pain, 
which may sometimes lead to exploratory laparotomies; consti-
pation, nausea and vomiting may be associated symptoms. The 
pain is usually followed by psychiatric disturbances which include 
confusion, delirium, hallucinations, and frank psychosis.[4,5] 
Autonomic instability with tachycardia and elevated blood pressure 
may be present and generalised tonic-clonic or partial seizures 
commonly occur. Mental changes may progress to coma. Only one of 
our patients presented with this typical clinical picture of abdominal 
pain followed by psychiatric disturbances and convulsions; the others 
showed varying degrees of intermittent confusion in the ward, but 
did not report any abdominal pain preceding admission.
Our patients all presented with an acute onset of progressive 
quadriparesis. However, the peripheral neuropathy of porphyria is 
reported to develop typically after the onset of abdominal pain and 
psychiatric disturbances. Three of our patients did not give any history 
of acute abdominal pain. Porphyric neuropathy may develop within 
3 - 75 days after the onset of abdominal pain,[6] and 80% of patients 
develop the neuropathy within 1 month. A study by Hift and Meissner[7] 
from SA reported that a sudden cessation of abdominal pain in an acute 
attack may actually constitute a warning of an incipient quadriparesis. 
These authors considered presentation without pain as highly atypical, a 
view that may, as in our patients, lead to consideration of Guillain-Barré 
syndrome as a cause for the severe weakness. One study from the USA, 
however, did not find a single case of porphyria in 450 patients with 
Guillain-Barré syndrome who were screened for the condition. [8] Our 
cases emphasise that in SA specifically, clinicians should have a high 
index of suspicion not only for VP, which is well known to have a high 
incidence in the white population, but also for AIP in patients of all 
population groups presenting with a Guillain-Barré-like picture.
The typical electrophysiological findings in porphyric neuro pathies 
show an axonal mainly motor neuropathy, with varying sensory 
involvement.[9,10] Previous reports have demonstrated that electro-
physiological improvement of the neuropathy can take many months. 
In one patient report, not all nerve conduction studies had returned 
to normal even after a period of over 21 months.[11] All our patients 
had low CMAP amplitudes on the nerve conduction studies of motor 
nerves, and in one patient, electrophysiological deterioration after 
2 months was documented, with absent responses of the ulnar and 
peroneal nerves that had previously been present. This was also the 
patient who did very poorly and died in the intensive care unit without 
regaining the ability to breathe autonomously. No specific reports 
were found that correlated CMAPs with prognosis in porphyric 
neuropathy, but studies in patients with Guillain-Barré syndrome 
have shown that a very low CMAP (<10% of normal) is associated 
with a poor outcome.[12] In our patient, a superimposed critical care 
neuropathy, as well as the severe hyponatraemia aggravated by the 
glucose solutions against which Hift and Meissner[7] have cautioned, 
may have contributed to the findings and poor outcome.
Information on the prognosis of porphyric neuropathy is limi-
ted. As mentioned, the degree of axonal damage probably pre dicts 
the ultimate prognosis and recovery often takes many months with 
some patients remaining permanently quadriparetic.[4,13] In the SA 
study that reported on clinical features recorded during 112 acute 
porphyric attacks, three patients with quadriparesis improved with 
rehabilitation and eventually regained the ability to walk. In the 
same study, several other patients with pre-existing neuropathy 
deteriorated markedly at the onset of a new attack, but the weakness 
resolved rapidly after haemin administration.[7] One patient with 
AIP improved even after a long period of being bedridden when a 
course of haemin was given,[14] and other authors similarly report a 
favourable outcome after haemin administration.[15] Unfortunately, 
the administration of haemin was delayed in most of our patients 
owing to local unavailability of the drug, which may have worsened 
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the outcome, since studies recommend early administration of 
haemin[7,16] to limit or reverse the toxic effects of haem precursors on 
the peripheral nerves.
Porphyric attacks can be precipitated by many factors, the most 
common being restricted caloric intake, alcohol, hormones and 
specific medications.[4] Interestingly, in two of our patients we believe 
that the attack was precipitated by antiretroviral medication – one 
patient was started on highly active antiretroviral therapy (HAART) 
before the onset of the symptoms, and the other took antiretroviral 
medication for post-exposure prophylaxis. In the first case, the 
patient received tenofovir, emtricitabine and efavirenz. Although 
not many reports linking acute porphyria with these medications 
are available, one recent report describes a patient with VP who 
developed an acute attack after receiving the same HAART.[17] Drugs 
that induce cytochrome P450 proteins (CYP), by causing haem 
depletion, lead to enhanced transcription of the rate-limiting enzyme 
of the haem biosynthetic pathway, 5-aminolaevulinate synthase.[17] 
Since antiretroviral drugs that induce CYP3A4 and 2C9 have the 
greatest porphyrinogenicity, it is likely that the efavirenz (a strong 
CYP3A4 inducer) in the abovementioned regimens precipitated the 
acute attacks.[17] Treating HIV infection in patients with porphyria is 
therefore challenging.
Conclusion
Our cases emphasise that acute and severe porphyric neuropathy 
can occur without preceding symptoms and that this condition 
should be considered in patients with a Guillain-Barré-like 
clinical presentation. It is important to note that attacks may 
be precipitated by antiretroviral therapy, and that in SA speci-
fically, care should be taken when prescribing HAART and 
antituberculosis drugs to patients with possible porphyria. The 
availability of haemin proved to be problematic in our setting, 
and streamlining the process of obtaining this medication should 
be made a priority in public hospitals.
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